Smith & Nephew reported revenue growth in the first quarter of 2016 over the same period last year. However, the emerging markets didn't fair so well.
Here are eight things to know about Smith & Nephew's financial report:
1. Revenue was up 4 percent in the first quarter to $1.1 billion, compared to the same period last year. The company had a 2 percent benefit from acquisitions.
2. Established markets revenue grew 6 percent; the United States led the way with an 8 percent revenue growth. However, revenue in emerging markets declined 6 percent. Weakness in China offset double-digit growth in most other countries and there was a significant slow-down in tendering and sales in the oil-dependent Gulf states.
3. The knee implant revenue was up 9 percent in the quarter while hip implant revenue jumped 4 percent. Sports medicine and the advanced would devices business grew 11 percent.
4. The trauma and extremities revenue was down 7 percent, with China and Gulf states decreases offsetting a strong showing in the United States. The advanced wound management business was flat.
5. United States revenue hit $563 million while the emerging markets reported $153 million. The other established markets revenue was reported as $421 million.
6. The company's largest market is the United States, where the quarter was successful. Smith & Nephew also reported sustainable improvements in the European market with four consecutive quarters of positive revenue growth last year.
7. The company continues to integrate Blue Belt Technologies' robotics-assisted orthopedic surgery business, which was acquired last year. Capital sales of the Navio system were included in the "other surgical business" segment, which reported 19 percent revenue growth.
8. Over the next year, Smith & Nephew's expectations for the group are unchanged from the previous report. "Overall, we continue to expect good underlying revenue growth in 2016 as we benefit from our investments in established businesses, acquisitions and pioneering technologies," said CEO Olivier Bohuon.